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Background
Monoclonal antibodies (mAbs) used in cancer therapy
may cause allergic/infusion reactions (AIRs). To assess
the scope of this problem, a pilot literature search was
conducted.
Methods
Using terms for oncology mAbs and AIRs, English-only
articles were searched in PubMed, EMBASE, and BIO-
SIS. The search was conducted on Nov 19, 2013, with
no date limiters. Cetuximab (C) and rituximab (R) were
among the most commonly reported mAbs, and these
were analyzed further. Articles were excluded if AIRs
couldn’t be quantified.
Results
940 articles met criteria, including 167 and 83 for C and
R, respectively, describing 19,861 and 5064 mAb-treated
patients. AIRs were reported in 1694 (8.5%) and 647
(12.3%) C and R patients, but these numbers may be
low as some articles only reported grade 3/4 or severe
reactions. Various terms were used to describe AIRs (eg,
anaphylaxis [AX], allergic reaction [AR], hypersensitivity
reaction [HR], infusion reaction [IR]), so it was often
difficult to distinguish the type of AIR. Some AIRs were
reported as grade 4 HRs but not specifically noted as
AX. Also, it was hard to attribute an AIR to a specific
agent when the mAb was part of combination therapy.
Grade 3/4 AIRs were noted in 633 (3.2%) and 215
(4.2%) C and R patients. AX specifically was noted in 88
(0.4%) and 64 (1.3%) C and R patients. Among C
patients, 13 fatalities were attributed to AIRs, with none
in the R group.
Conclusions
Although a well-known adverse event, the magnitude of
AIRs with C and R still may be underappreciated. The
presence of the galactose-galactose epitope in mAbs
produced in murine cell lines, as with C, contributes to
AIRs. The frequency of AIRs was likely underestimated
in this review due to limited reporting in the medical lit-
erature and varied classification. Various AIR terms
were used interchangeably, sometimes within a single
article. Grade 4 AIRs were not always labeled as AX.
Grade 3/4, AX, or fatal AIRs were rare but are clinically
significant when they occur. Management of AIRs often
was not reported, nor was the incidence of delayed
AIRs, which may have been unknown. This suggests a
need for more standardized reporting of AIRs. Appro-
priate steps for prevention/treatment of AIRs should be
taken when these mAbs are utilized. Readily available
therapies for the treatment of AIRs may be helpful (eg,
epinephrine autoinjectors); however, these products are
not indicated for patients at risk for delayed AIRs.
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